FDA approves regorafenib for advanced gastrointestinal stromal tumours

The USA Food and Drug Administration expanded the approved use of regorafenib to treat patients with advanced gastrointestinal stromal tumors (GIST) that can not be surgically removed and no longer respond to other FDA-approved treatments for this disease. Regorafenib (Stivarga), a multi-kinase inhibitor, blocks several enzymes that promote cancer growth. With this new approval, Stivarga is intended to be used in patients whose GIST tumour can not be removed by surgery or has metastasize and is no longer responding to Gleevec (imatinib) and Sutent (sunitinib), two other FDA-approved drugs to treat GIST. Read more here.